SI-BONE SIBN
SI-BONE FY 2023: revenue $138.9M, up 31%; diluted EPS −$1.13
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001459839-24-000014
Key figures from this report
These are the numbers SI-BONE reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$138.9M+31% from $106.4M in FY 202210-K income statement, on EDGAR
- Net income−$43.3MAgainst −$61.3M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$1.13Against −$1.79 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$33.3M+61% from $20.7M in FY 202210-K balance sheet, on EDGAR
- Cash from operations−$18.7MAgainst −$41.7M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Biolife Solutions BLFS public float $845M, Jun 30, 2025
- Embecta EMBC public float $732M, Mar 31, 2025, over 18 months old
- Mimedx Group MDXG public float $719M, Jun 30, 2025
- Heartflow HTFL
- Integra Lifesciences Holdings IART public float $925M, Jun 30, 2025
